GBL to invest in Rayner alongside CVC, to support growth acceleration

A significant investment is set to reshape the landscape of surgical ophthalmology. GBL will acquire a co-controlling minority stake in Rayner, a global leader in the field, through a €0.5 billion equity investment from CVC Capital Partners VIII.

Rayner’s Growth and Innovation

Rayner, which operates in over 80 countries and serves more than 3 million patients annually, has experienced substantial growth since CVC’s initial investment in 2021. This growth has been fueled by significant investment in research and development, manufacturing and infrastructure. The company boasts a portfolio of ophthalmic products, including Intraocular Lenses (IOLs), consumables like OMIDRIA® and Ophteis OVDs, and the SOPHI Phaco platform.

Did You Know? Rayner developed the world’s first Intraocular Lens (IOL) in 1949, marking a pivotal moment in vision correction.

Pioneering Technology

Rayner is at the forefront of intraocular lens technology, having recently launched the GalaxyTM spiral IOL. This innovative lens aims to provide patients with a smooth, continuous range of vision while minimizing side effects and ensuring zero loss of transmitted light. The company also offers a suite of digital tools designed to enhance convenience for both surgeons and patients.

Partnership and Future Outlook

GBL will partner with both CVC and Rayner’s existing management team to support the company’s international expansion plans. Both GBL and CVC are focused on scaling Rayner through organic growth and strategic mergers and acquisitions (M&A).

Expert Insight: This investment signals strong confidence in Rayner’s position within the ophthalmic market and suggests a long-term commitment to innovation and expansion. The combined resources of GBL and CVC could accelerate the company’s growth trajectory and potentially lead to further advancements in surgical eye care.

Tim Clover, CEO of Rayner, stated the transaction is “an exciting milestone” for the company, particularly given recent investments in R&D and FDA approvals. Phil Robinson, Partner at CVC, highlighted Rayner’s growth since 2021 and expressed enthusiasm for collaborating with GBL to build upon existing foundations.

Frequently Asked Questions

What is the primary focus of this investment?

The primary focus is to support Rayner’s international growth ambitions through a combination of organic expansion and strategic mergers and acquisitions.

Who are the key players involved in this transaction?

The key players are Rayner, GBL, and CVC Capital Partners VIII. GBL is investing in Rayner, while CVC will remain a lead investor.

What types of products does Rayner offer?

Rayner offers a range of ophthalmic products, including monofocal and premium Intraocular Lenses (IOLs), ophthalmic consumables like OMIDRIA® and Ophteis OVDs, the SOPHI Phaco platform, and digital tools.

How might increased investment impact the future of ophthalmic technology and patient care?